The 201 Clinical Trial For Patients With Untreated Parkinson’s Disease
The 201 Clinical Trial is a trial that will explore whether a novel drug, Risvodetinib (IkT-148009), can slow or halt progression of Parkinson’s disease. The trial will also evaluate whether Risvodetinib (IkT-148009) can partially or completely restore lost function.
I encourage anyone who is newly diagnosed and not taking medication to participate. I would do it in a heartbeat if I weren't already on medication and therefore disqualified.
"Inhibikase Therapeutics’ lead product candidate, Risvodetinib (IkT-148009), is a potent, selective small-molecule medication designed and engineered as chronically administered, once-daily oral medication targeting the underlying biological mechanism resulting in Parkinson’s disease, with the goal of halting disease progression and reversing functional loss. Risvodetinib (IkT-148009) is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms."
You go salted! Being part of clinical trials has transformed my approach to my disease. It is rewarding and hopeful. I hope you get accepted but keep after it if you don't. My first trial I was chucked out on my first appointment after screening. It was devastating. Take each day as it comes and keep applying. I've now been involved with 5 trials (if you include PPMI). I'm slated to start my sixth in January.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.